Vertex (VRTX) Up 0.2% Since Last Earnings Report: Can It Continue?
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo Finance
Updated Jun 2, 2026
Upgrade to a paid plan to see AI rating history on the chart.
Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
If you are wondering whether Vertex Pharmaceuticals at around US$438 per share is priced attractively or already reflects its strengths, you are not alone. The…
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQVnFxRXB4TG1ZTFNFbmJKMUVlUmwxWjkxdFgwckRHV2FtX0w2YzMyaW5mVjdLRW1FcktyZUFDRlpra2pOY3BIc3d3X0x1cjFnb…
Vertex Pharmaceuticals recently reported that the FDA accepted its Biologics License Application for povetacicept in adults with immunoglobulin A nephropathy,…
Vertex Pharmaceuticals (NASDAQ:VRTX) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates sub…
VRTX moves closer to a potential nephrology launch as the FDA accepts its BLA for povetacicept in adults with IgAN, with a decision due in November 2026.
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOYTJ2VzdBLWE5dW5ERWRtY0N0MWxTZ1RhTmVEQzRRMnpySFQxeHZvdVRMUjFzVUpRa0VCd1ZRSThxVXhVTlIwOEF4eDZBUllMb…
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxPVzBaSG8tTXJoOGhTRFo0aVNBa0ZGSGtnQXJEUlRPdUVISWt6OEVnRjk2OW15TkNMTThpbUhDU0xpTzBVWkU4b05UNnhxNWIzM…
Not investment advice. Past performance does not guarantee future results. Full disclaimer